NCT07190053View on ClinicalTrials.gov

Long Term Treatment Strategies and Effectiveness of Secukinumab in Patient With JIA Subtypes of JPsA and ERA: Study From German BIKER Registry.

Not yet recruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

September 18, 2029

Study Completion Date

September 18, 2029

Conditions
Enthesitis-related Arthritis (ERA)Juvenile Psoriatic Arthritis (JPsA)
Interventions
OTHER

Secukinumab

This is an observational study, there is no treatment allocation

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY